登录

Meio CadiNav Medical Completes Pre-Series A Financing

作者: Mailman 2021-08-23 16:34
梅奥心磁
企业数据由 动脉橙 提供支持
心脏介入手术机器人研发商 | A+轮 | 运营中
中国-浙江
2023-08-14
创瑞投资
查看

(VCBeat) Aug. 09, 2021 -- Meio CadiNav Medical, a robotics company for interventional cardiovascular surgery, has closed on a Pre-Series A financing package. The proceeds will be used to build a cleanroom system compliant with GMP and promote clinical trials of the "Titian" robot for navigation in cardiac electrophysiology.


This round of financing is invested by TusStar, with Mingxi Capital acting as the exclusive financial advisor for the transaction.


Meio CadiNav Medical was founded in June 2018 by Dr. Chen Yuemeng and Professor Lu Caiyi, director of the Department of Cardiology, 301 Hospital. Meio CadiNav Medical is committed to the research and development of surgical navigation techniques and interventional surgical robots in the department of cardiology, as well as the development of magnetic navigation platform and consumable product for magnetically guiding in cardiac surgery. The company has established a research and development barrier based on its own intellectual property rights. It has obtained 27 patents and filed for 47 patent applications. It has self-developed the "Titian" robot and the "Raphaello" surgical robot – a flexible magnetic navigation stereopositioning and precision ablation system.


Meio CadiNav Medical is headquartered in Shaoxing, Zhejiang province, with core research and development centers in Shanghai, Hangzhou and Shaoxing. In the first half of 2021, Meio CadiNav Medical has successfully completed animal experiments of "Titian".


Since its inception, Meio CadiNav Medical has been committed to becoming a leader in Robotic cardiac surgery, developing intelligent cath lab surgical solutions, and winning recognition from society.


>>>>

About TusStar


Founded in 1999 and headquartered in Beijing, China, TusStar is an investment firm that integrates innovation services and building business platforms. The company has incubated over 5000 firms, among which are excellent companies, including 49 Diamond Companies, 45 Golden Seed Project companies, and 34 listed companies as well as great entrepreneurs including 81 leading talents from RecruitmentProgram of Global Experts, Overseas Talent Pooling Program, and High-end Leading Talent Pooling Program.

相关赛道 医疗机器人
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

完成近亿美元D轮融资,平安资本领投的润迈德医疗如何让“无人手术室”概念落地?

辰德资本合伙人谈庆:狙击医疗器械创新,技术变革带动市场新机遇【投资人说】

EDDA Technology Secures $150 Million in New Financing Round

Yi Chao Medical Announces ¥10M Series A Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Ruijian Pharma Scoops up ¥100 Million in Series A Financing

2021-08-23
下一篇

Kangle Weishi Receives ¥1.015 Billion pre-IPO Investment

2021-08-23